Upcoming EL-PFDD Meetings
To promote transparency and communication, FDA is sharing a list of disease areas where a letter of intent (LOI) has been submitted and ongoing plans exist for a future Externally-Led PFDD meeting. While multiple organizations may be working together, the organizations listed below are the primary points of contact for any questions regarding their EL-PFDD meeting.
FDA does not conduct Externally-Led PFDD meetings and a listing on this webpage does not reflect endorsement.
Disease or Condition |
Organization Submitting LOI |
Organization Contact |
Anticipated Meeting Date |
---|---|---|---|
Cerebral Creatine Deficiency Syndromes |
Association for Creatine Deficiencies |
Celeste Graham |
January 24, 2023 |
Pemphigus and Pemphigoid |
International Pemphigus and Pemphigoid Foundation |
Marc Yale |
January 25, 2023 |
Autoimmune Hepatitis |
Autoimmune Hepatitis Association |
Erin Anderson |
January 27, 2023 |
Wiskott-Aldrich Syndrome |
Wiskott-Aldrich Foundation |
Sumathi Iyengar |
February 3, 2023 |
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) |
SADS Foundation |
Alice Lara |
June 20, 2023 |
Questions?
To contact FDA’s CDER Patient-Focused Drug Development Program Staff, please email patientfocused@fda.hhs.gov.
To get updates about CDER's Patient-Focused Drug Development programs, subscribe to our free email subscription service using the button at the top of the page.